New eye drug shows promise in battle against blinding disease

This study tested a new medicine called JL14002 against a standard treatment (ranibizumab) for wet age-related macular degeneration, a leading cause of vision loss. 443 adults aged 50-80 with active disease received injections into the eye. The main goal was to see if JL14002 improved vision as well as the standard drug over 12 weeks, with follow-up for a year. The approach aims to control the disease and preserve sight.